152 related articles for article (PubMed ID: 18332046)
1. A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients.
Woelfelschneider A; Popanda O; Lilla C; Linseisen J; Mayer C; Celebi O; Debus J; Bartsch H; Chang-Claude J; Schmezer P
Carcinogenesis; 2008 Sep; 29(9):1758-64. PubMed ID: 18332046
[TBL] [Abstract][Full Text] [Related]
2. Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer.
Borchiellini D; Etienne-Grimaldi MC; Bensadoun RJ; Benezery K; Dassonville O; Poissonnet G; Llorca L; Ebran N; Formento P; Château Y; Thariat J; Milano G
Oral Oncol; 2017 Apr; 67():70-76. PubMed ID: 28351583
[TBL] [Abstract][Full Text] [Related]
3. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer.
Zhou W; Liu G; Park S; Wang Z; Wain JC; Lynch TJ; Su L; Christiani DC
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):491-6. PubMed ID: 15734977
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
6. Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies.
Ding YW; Gao X; Ye DX; Liu W; Wu L; Sun HY
Clin Transl Oncol; 2015 Sep; 17(9):710-9. PubMed ID: 26022132
[TBL] [Abstract][Full Text] [Related]
7. A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study.
Hansen RD; Sørensen M; Tjønneland A; Overvad K; Wallin H; Raaschou-Nielsen O; Vogel U
BMC Cancer; 2008 Feb; 8():54. PubMed ID: 18289367
[TBL] [Abstract][Full Text] [Related]
8. The Contribution of Excision Repair Cross-complementing Group 1 Genotypes to Colorectal Cancer Susceptibility in Taiwan.
Yueh TC; Chou AK; Gong CL; Fu CK; Pei JS; Wu MH; Tsai CW; Chang WS; Hsiao CL; Yen ST; Li HT; Bau DT
Anticancer Res; 2017 May; 37(5):2307-2313. PubMed ID: 28476796
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
Huang ZH; Hua D; Du X; Li LH; Mao Y; Liu ZH; Song MX; Zhou XK
World J Gastroenterol; 2008 Nov; 14(41):6401-7. PubMed ID: 19009659
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Valdivia-Bautista J; Faus-Dáder MJ; Calleja-Hernández MÁ
Pharmacogenomics J; 2019 Apr; 19(2):164-177. PubMed ID: 29662106
[TBL] [Abstract][Full Text] [Related]
13. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
14. Rs3212986 polymorphism, a possible biomarker to predict smoking-related lung cancer, alters DNA repair capacity via regulating ERCC1 expression.
Yu T; Xue P; Cui S; Zhang L; Zhang G; Xiao M; Zheng X; Zhang Q; Cai Y; Jin C; Yang J; Wu S; Lu X
Cancer Med; 2018 Dec; 7(12):6317-6330. PubMed ID: 30453383
[TBL] [Abstract][Full Text] [Related]
15. ERCC1, XPD and RAI mRNA levels in lymphocytes are not associated with lung cancer risk in a prospective study of Danes.
Vogel U; Nexø BA; Tjønneland A; Wallin H; Hertel O; Raaschou-Nielsen O
Mutat Res; 2006 Jan; 593(1-2):88-96. PubMed ID: 16054657
[TBL] [Abstract][Full Text] [Related]
16. Excision repair of BPDE-adducts in human lymphocytes: diminished capacity associated with ERCC1 C8092A (rs3212986) polymorphism.
Yu T; Liu Y; Lu X; Xiao S; Cai Y; Jin C; Liu Q; Yang J; Wu S; Bao X; Pan L; van der Straaten T
Arch Toxicol; 2013 Apr; 87(4):699-709. PubMed ID: 23203453
[TBL] [Abstract][Full Text] [Related]
17. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
[TBL] [Abstract][Full Text] [Related]
18. Laryngeal cancer risk and common single nucleotide polymorphisms in nucleotide excision repair pathway genes ERCC1, ERCC2, ERCC3, ERCC4, ERCC5 and XPA.
Lu B; Li J; Gao Q; Yu W; Yang Q; Li X
Gene; 2014 May; 542(1):64-8. PubMed ID: 24582975
[TBL] [Abstract][Full Text] [Related]
19. Association of single nucleotide polymorphisms of DNA repair genes in NER pathway and susceptibility to pancreatic cancer.
Zhao F; Shang Y; Zeng C; Gao D; Li K
Int J Clin Exp Pathol; 2015; 8(9):11579-86. PubMed ID: 26617894
[TBL] [Abstract][Full Text] [Related]
20. Contribution of excision repair cross-complementing group 1 genotypes to triple negative breast cancer risk.
Tsai CW; Chang WS; Shen TC; Su CH; Wang HC; Liu LC; Bau DT
PLoS One; 2018; 13(8):e0202112. PubMed ID: 30096175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
